Regorafenib
Summary
Regorafenib is a kinase inhibitor used to treat patients with metastatic colorectal cancer, unresectable, locally advanced, or metastatic gastrointestinal stromal tumors, and hepatocellular carcinoma.
Brand Names: Stivarga
Generic Name: Regorafenib
DrugBank Accession Number: DB08896
Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Weight Average: 482.815
Monoisotopic: 482.076880893
Chemical Formula: C21H15ClF4N4O3